

Jian-Hong Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3111034/publications.pdf>

Version: 2024-02-01

157
papers

4,087
citations

159358

30
h-index

155451

55
g-index

158
all docs

158
docs citations

158
times ranked

4485
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 147-158.	0.7	21
2	Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1063-1074.	2.0	26
3	Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matching analysis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1078-1086.	0.5	1
4	Microwave ablation versus laparoscopic resection as first-line therapy for solitary ≤ 5 cm HCC. <i>Hepatology</i> , 2022, 76, 66-77.	3.6	40
5	Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 782-794.	1.4	14
6	Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis. <i>BJS Open</i> , 2022, 6, .	0.7	9
7	Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 4291-4303.	0.7	23
8	Association of CK19 expression with the efficacy of adjuvant transarterial chemoembolization after hepatic resection in hepatocellular carcinoma patients at high risk of recurrence.. <i>Journal of Clinical and Translational Research</i> , 2022, 8, 71-79.	0.3	0
9	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 955-964.	0.7	9
10	Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	3
11	Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis. <i>Surgery</i> , 2021, 169, 911-920.	1.0	29
12	Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. <i>Bioscience Reports</i> , 2021, 41, .	1.1	2
13	Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. <i>Frontiers in Oncology</i> , 2021, 11, 700228.	1.3	6
14	Macrophage polarization-associated Inc-Ma301 interacts with caprin-1 to inhibit hepatocellular carcinoma metastasis through the Akt/Erk1 pathway. <i>Cancer Cell International</i> , 2021, 21, 422.	1.8	12
15	The upward trend in the immunotherapy utilization for hepatobiliary cancers. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 692-695.	0.7	8
16	Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study. <i>British Journal of Surgery</i> , 2021, 109, 71-78.	0.1	21
17	S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 114-126.	1.9	14
18	Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2021, 274, e1209-e1217.	2.1	45

#	ARTICLE	IF	CITATIONS
19	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 737497.	1.3	22
20	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. <i>Frontiers in Oncology</i> , 2021, 11, 783339.	1.3	4
21	The lncRNA SNHG16 affects prognosis in hepatocellular carcinoma by regulating p62 expression. <i>Journal of Cellular Physiology</i> , 2020, 235, 1090-1102.	2.0	44
22	Outcomes of anatomical versus non-anatomical resection for hepatocellular carcinoma according to circulating tumour-cell status. <i>Annals of Medicine</i> , 2020, 52, 21-31.	1.5	16
23	Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. <i>Gut</i> , 2020, 69, 1900-1902.	6.1	13
24	Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 6437-6444.	1.2	10
25	Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 749-756.	1.4	8
26	Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 3400-3406.	1.2	11
27	Dose-Response Between Serum Prealbumin and All-Cause Mortality After Hepatectomy in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 596691.	1.3	8
28	Development and validation of a nomogram for assessing survival in patients with hepatocellular carcinoma after hepatectomy. <i>Bioscience Reports</i> , 2020, 40, .	1.1	5
29	Response to Comment on "Development and Validation of a Nomogram to Preoperatively Estimate Post-Hepatectomy Liver Dysfunction Risk and Long-Term Survival in Patients With Hepatocellular Carcinoma". <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, e791-e792.	2.1	3
30	Analysis of Clinicopathological Characteristics and Prognosis of Young Patients with Hepatocellular Carcinoma after Hepatectomy. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-7.	0.7	9
31	Letter: sex disparity in prognosis of patients with hepatocellular carcinoma after resection. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1767-1768.	1.9	2
32	Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. <i>American Journal of Surgery</i> , 2019, 217, 739-744.	0.9	53
33	Evaluation of liver regeneration and post-hepatectomy liver failure after hemihepatectomy in patients with hepatocellular carcinoma. <i>Bioscience Reports</i> , 2019, 39, .	1.1	17
34	Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 6011-6018.	0.9	21
35	Serum Prealbumin is Negatively Associated with Survival in Hepatocellular Carcinoma Patients after Hepatic Resection. <i>Journal of Cancer</i> , 2019, 10, 3006-3011.	1.2	10
36	Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1077-1088.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1460-1467.	0.5	49
38	Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 616-617.	1.9	0
39	Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 2545-2552.	1.3	8
40	Systematic review of treatment strategy for recurrent hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, 101-107.	0.4	26
41	The role of SSM and LSPS in predicting posthepatectomy liver failure should be further evaluated. <i>Journal of Surgical Oncology</i> , 2019, 119, 402-403.	0.8	0
42	Correlation between serum prealbumin and prognosis of patients with hepatocellular carcinoma after hepatectomy. <i>Journal of Surgical Oncology</i> , 2019, 119, 794-800.	0.8	20
43	A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7cm and multiple tumours beyond up to seven criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 202-210.	1.9	22
44	Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediate to Advanced Stage Hepatocellular Carcinoma: A Comment For Moving Forward. <i>Hepatology</i> , 2019, 70, 446-447.	3.6	5
45	Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1026-1037.	1.0	30
46	We're Still in an Update Process of the BCLC System. <i>Annals of Surgery</i> , 2018, 267, e23-e24.	2.1	9
47	Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. <i>Hpb</i> , 2018, 20, 110-119.	0.1	35
48	Contrast-Enhanced Ultrasound to Monitor Early Recurrence of Primary Hepatocellular Carcinoma after Curative Treatment. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	8
49	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	1.8	360
50	Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus. <i>Cancer Medicine</i> , 2018, 7, 4387-4395.	1.3	20
51	Hepatic resection for elderly patients with hepatocellular carcinoma: a systematic review of more than 17,000 patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1059-1068.	1.4	19
52	Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. <i>Cancer Research</i> , 2018, 78, 4731-4744.	0.4	204
53	Prognostic value of PD-L1 expression in patients with primary solid tumors. <i>Oncotarget</i> , 2018, 9, 5058-5072.	0.8	47
54	Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 11-13.	1.8	9

#	ARTICLE	IF	CITATIONS
55	Postoperative Antiviral Therapy With Nucleos(t)ide Analogs in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2017, 265, e46-e47.	2.1	7
56	Transarterial Embolization With or Without Chemotherapy: What Should Be the Indication for Patients With Hepatocellular Carcinoma?. <i>Journal of Clinical Oncology</i> , 2017, 35, 257-258.	0.8	5
57	Hepatectomy for liver metastases from gastric cancer: a systematic review. <i>BMC Surgery</i> , 2017, 17, 14.	0.6	27
58	High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 42199.	1.6	23
59	Improving patient selection for selective internal radiation therapy of intrahepatic cholangiocarcinoma: A meta-regression study. <i>Liver International</i> , 2017, 37, 1056-1064.	1.9	35
60	Pre- and postoperative HBsAg levels may predict recurrence and survival after curative resection in patients with HBV-associated hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 140-148.	0.8	13
61	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 67, 885-886.	1.8	10
62	Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 891-897.	1.2	22
63	Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure. <i>Cancer Medicine</i> , 2017, 6, 2357-2369.	1.3	42
64	Optimizing stage of single large hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e6608.	0.4	10
65	Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 562-563.	1.9	2
66	Letter: older age and male gender increase the risk of hepatocellular carcinoma after hepatitis B surface antigen (HBsAg) seroclearance. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 906-908.	1.9	2
67	Hepatic resection is superior to transarterial chemoembolization for treating intermediate-stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1083-1084.	1.9	5
68	Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. <i>Oncotarget</i> , 2017, 8, 18537-18549.	0.8	9
69	A New Theranostic System Based on Endoglin Aptamer Conjugated Fluorescent Silica Nanoparticles. <i>Theranostics</i> , 2017, 7, 4862-4876.	4.6	30
70	Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. <i>Oncotarget</i> , 2017, 8, 33911-33921.	0.8	62
71	Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. <i>PLoS ONE</i> , 2017, 12, e0174222.	1.1	10
72	New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 169-176.	0.7	24

#	ARTICLE	IF	CITATIONS
73	Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 15047-15056.	0.8	15
74	Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. <i>Oncotarget</i> , 2017, 8, 51810-51816.	0.8	6
75	Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. <i>Oncotarget</i> , 2017, 8, 18296-18302.	0.8	54
76	Is laparoscopic hepatectomy superior to open hepatectomy for hepatocellular carcinoma?. <i>World Journal of Hepatology</i> , 2017, 9, 167.	0.8	4
77	Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. <i>World Journal of Hepatology</i> , 2016, 8, 957.	0.8	20
78	Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6897-6907.	1.0	7
79	Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <math>\leq 500</math> copies/mL. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4593-4603.	1.0	10
80	Association of the miR-196a2 C>T and miR-499 A>G polymorphisms with hepatitis B virus-related hepatocellular carcinoma risk: an updated meta-analysis. <i>OncoTargets and Therapy</i> , 2016, 9, 2111.	1.0	8
81	Are another 5 years of adjuvant aromatase inhibitor therapy needed?. <i>Breast Cancer: Targets and Therapy</i> , 2016, Volume 8, 207-209.	1.0	0
82	Comment on "Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis". <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-2.	0.8	3
83	Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e2722.	0.4	38
84	Albumin<sup>2</sup>bilirubin <i>versus</i> Child<sup>2</sup>Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 725-734.	0.1	242
85	Comparison of postoperative immune function in patients with thoracic esophageal cancer after video-assisted thoracoscopic surgery or conventional open esophagectomy. <i>International Journal of Surgery</i> , 2016, 30, 155-160.	1.1	12
86	Association of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: A cautionary comment. <i>Journal of Hepatology</i> , 2016, 65, 228.	1.8	0
87	Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: A comment for moving forward. <i>Journal of Hepatology</i> , 2016, 65, 230-231.	1.8	2
88	Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion?. <i>Journal of Hepatology</i> , 2016, 65, 1057-1058.	1.8	8
89	Therapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review. <i>Oncology Letters</i> , 2016, 11, 3849-3857.	0.8	3
90	Letter: clinical outcomes of ^HAg loss in chronic ^{HBV} infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 535-536.	1.9	2

#	ARTICLE	IF	CITATIONS
91	Association between age and overall survival of patients with hepatocellular carcinoma after hepatic resection. <i>Journal of Surgical Oncology</i> , 2016, 114, 966-970.	0.8	16
92	Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?. <i>Liver International</i> , 2016, 36, 1715-1715.	1.9	6
93	Controversies and evidence of hepatic resection for hepatocellular carcinoma. <i>BBA Clinical</i> , 2016, 6, 125-130.	4.1	16
94	Comment on stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 113, 715-715.	0.8	2
95	Are We Sure that Blood Transfusion is Associated with Recurrence of Hepatocellular Carcinoma After Hepatectomy?. <i>World Journal of Surgery</i> , 2016, 40, 2291-2292.	0.8	0
96	Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy. <i>Molecular and Clinical Oncology</i> , 2016, 5, 3-6.	0.4	3
97	Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 2435-2441.	0.8	22
98	Subclassification of patients with solitary hepatocellular carcinoma based on post-hepatectomy survival: a large retrospective study. <i>Tumor Biology</i> , 2016, 37, 5327-5335.	0.8	6
99	Comment on tumor size as a prognostic factor for solitary HCC after resection. <i>Journal of Surgical Oncology</i> , 2016, 113, 593-593.	0.8	3
100	A premature proposal for new liver cancer seromarkers. <i>Tumor Biology</i> , 2016, 37, 4293-4294.	0.8	0
101	Postoperative antiviral therapy with nucleos(t)ide analogs for patients with hepatitis B virus-related hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, e29-e30.	0.7	3
102	Combination of 5-fluorouracil and 2-morpholino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity. <i>Tumor Biology</i> , 2016, 37, 10943-10958.	0.8	7
103	Efficacy of triclosan-coated sutures for reducing risk of surgical site infection in adults: a meta-analysis of randomized clinical trials. <i>Journal of Surgical Research</i> , 2016, 201, 105-117.	0.8	51
104	Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi. <i>Tumor Biology</i> , 2016, 37, 5879-5884.	0.8	14
105	Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after surgery: A comment for moving forward. <i>World Journal of Hepatology</i> , 2016, 8, 605.	0.8	2
106	The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 8271-8272.	0.8	9
107	Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma?. <i>Tumor Biology</i> , 2015, 36, 8273-8274.	0.8	2
108	Letter: pre- and post-operative anti-viral therapy is important for patients with hepatitis B virus-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 789-790.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis. <i>BMJ Open</i> , 2015, 5, e008263.	0.8	9
110	Is drug-eluting bead transcatheter arterial chemoembolization (TACE) associated with better tumor response than conventional TACE in a meta-analysis?: Authors' reply. <i>Hepatology Research</i> , 2015, 45, 1260-1261.	1.8	0
111	Portal hypertension should not be a contraindication of hepatic resection to treat hepatocellular carcinoma with compensated cirrhosis. <i>Hepatology</i> , 2015, 62, 977-978.	3.6	13
112	Postoperative hepatitis B virus reactivation and surgery-induced immunosuppression in patients with hepatitis B-related hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 634-642.	0.8	13
113	Comment on: Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 907-908.	0.8	1
114	Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion. <i>Medicine (United States)</i> , 2015, 94, e396.	0.4	110
115	Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1426.	0.4	26
116	Comment on a meta-analysis comparing hepatic resection or transarterial chemoembolization as initial treatment for hepatocellular carcinoma. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5623.	2.0	2
117	Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 9630.	1.4	32
118	Possible associations between ascites and vascular invasion in patients with hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 4933-4934.	0.8	1
119	Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. <i>Medicine (United States)</i> , 2015, 94, e1968.	0.4	18
120	Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. <i>BMJ Open</i> , 2015, 5, e007258-e007258.	0.8	15
121	Hepatic Resection Improves Long-Term Survival of Patients with Large and/or Multinodular Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2288-2289.	0.9	2
122	Retrobulbar metastasis and intracranial invasion from postoperative hepatocellular carcinoma: A case report and review of the literature. <i>Oncology Letters</i> , 2015, 9, 721-726.	0.8	7
123	Intermediate-stage HCC "upfront resection" can be feasible. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 295-295.	12.5	21
124	Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 6277-6284.	0.8	15
125	Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 190-200.	1.8	73
126	Properly assessing CD133 as a risk factor for poor prognosis in patients with hepatocellular carcinoma after resection. <i>Tumor Biology</i> , 2015, 36, 4937-4938.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Adjuvant Immunotherapy for Postoperative Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 1639-1640.	0.6	2
128	Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension: Table A1. <i>Gut</i> , 2015, 64, 520.2-521.	6.1	48
129	Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: Propensity score analysis. <i>World Journal of Gastroenterology</i> , 2015, 21, 4627-4634.	1.4	47
130	Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5541-5547.	0.5	21
131	Efficacy of hepatic resection for huge (≥10 cm) hepatocellular carcinoma: good prognosis associated with the uninodular subtype. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 20581-8.	1.3	6
132	Impact of Diabetes Mellitus on the Prognosis of Patients with Hepatocellular Carcinoma after Curative Hepatectomy. <i>PLoS ONE</i> , 2014, 9, e113858.	1.1	28
133	Comparison of Long-Term Survival of Patients with Solitary Large Hepatocellular Carcinoma of BCLC Stage A after Liver Resection or Transarterial Chemoembolization: A Propensity Score Analysis. <i>PLoS ONE</i> , 2014, 9, e115834.	1.1	32
134	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. <i>Tumor Biology</i> , 2014, 35, 8451-8459.	0.8	25
135	Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. <i>Tumor Biology</i> , 2014, 35, 9459-9468.	0.8	22
136	Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 8355-8358.	0.8	17
137	Postoperative therapy options for hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 649-661.	0.6	53
138	Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. <i>Tumor Biology</i> , 2014, 35, 12779-12784.	0.8	22
139	Pre-, Peri-, and Postoperative Oral Administration of Branched-Chain Amino Acids for Primary Liver Cancer Patients for Hepatic Resection: A Systematic Review. <i>Nutrition and Cancer</i> , 2014, 66, 517-522.	0.9	10
140	Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 3069-3076.	0.7	44
141	Try113His and His139Arg polymorphisms in the microsomal epoxide hydrolase gene are not associated with risk of breast cancer. <i>Tumor Biology</i> , 2014, 35, 8087-8093.	0.8	0
142	Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2014, 260, 329-340.	2.1	382
143	Hepatic Resection Is Safe and Effective for Patients with Hepatocellular Carcinoma and Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108755.	1.1	46
144	Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. <i>World Journal of Hepatology</i> , 2014, 6, 652.	0.8	13

#	ARTICLE	IF	CITATIONS
145	mEH Tyr113His polymorphism and the risk of ovarian cancer development. <i>Journal of Ovarian Research</i> , 2013, 6, 40.	1.3	10
146	Zoledronate for Metastatic Bone Disease and Pain: A Meta-Analysis of Randomized Clinical Trials. <i>Pain Medicine</i> , 2013, 14, 257-264.	0.9	18
147	Postoperative Use of the Chemopreventive Vitamin K2 Analog in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e58082.	1.1	27
148	Single Nucleotide Polymorphism 8q24 rs13281615 and Risk of Breast Cancer: Meta-Analysis of More than 100,000 Cases. <i>PLoS ONE</i> , 2013, 8, e60108.	1.1	15
149	Meta-Analysis of Microsomal Epoxide Hydrolase Gene Polymorphism and Risk of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e57064.	1.1	23
150	Comparison of Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma after Liver Resection or Transarterial Chemoembolization. <i>PLoS ONE</i> , 2013, 8, e68193.	1.1	133
151	Methylenetetrahydrofolate Reductase Gene Polymorphism and Risk of Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2013, 8, e74521.	1.1	24
152	Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. <i>Cancer Biology and Medicine</i> , 2013, 10, 158-64.	1.4	48
153	Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. <i>European Journal of Surgical Oncology</i> , 2012, 38, 286-295.	0.5	71
154	Epidermal Growth Factor Gene Polymorphism and Risk of Hepatocellular Carcinoma: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e32159.	1.1	47
155	Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. <i>International Journal of Clinical Practice</i> , 2012, 66, 21-27.	0.8	36
156	Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 645-651.	0.6	7
157	Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. <i>Hepatology Research</i> , 2010, 40, 943-953.	1.8	94